Depersonalization/derealization disorder (DPDR) is one of the most misrecognized conditions in psychiatry, despite a lifetime prevalence comparable to schizophrenia or bipolar I. Patients describe feeling detached from their own thoughts, body, or surroundings while reality testing remains intact, and they often spend years cycling through neurology, cardiology, and primary care before the diagnosis is named. DSM-5-TR classifies DPDR within the dissociative disorders alongside dissociative identity disorder and dissociative amnesia, while ICD-11 places it in chapter 06 under dissociative disorders with broadly similar criteria. The clinical bottom line is recognition first, then a stepped approach: rule out medical and substance-induced mimics, treat comorbid anxiety, depression, and trauma, and offer trauma-focused or cognitive-behavioral psychotherapy. Pharmacotherapy plays a supporting role rather than a primary one. Early diagnosis shortens the diagnostic odyssey and reduces iatrogenic harm from unnecessary workup.

Transient depersonalization is common after acute stress, sleep deprivation, or cannabis use, but the full disorder is meaningful and persistent. Recognition rates remain low in primary care and emergency settings, contributing to a long lag between symptom onset and diagnosis.

Prevalence and demographics

• Lifetime prevalence of DPDR is approximately 1-2% in community samples, with 12-month prevalence near 0.8-1.9%.^1-2
• Brief or transient Depersonalization experiences occur in roughly 50% of the general population at some point, but most do not meet criteria for the disorder.^1,3
• Sex distribution is approximately equal, in contrast to most dissociative and anxiety disorders.^2,4
• Mean age of onset is mid-adolescence, typically 16 years, with 95% of cases beginning before age 25.^2,4
• Onset after age 40 is rare and should prompt a careful search for medical, neurologic, or substance-induced causes.⁴

Comorbidity

• Lifetime comorbid major depressive disorder occurs in roughly 70-90% of patients with DPDR.^2,5
• Anxiety disorders, particularly panic disorder, social anxiety disorder, and generalized anxiety disorder, co-occur in over half of cases.^2,5
• Personality disorders, especially avoidant, borderline, and obsessive-compulsive, are common.²
• Substance use, particularly cannabis and hallucinogens, frequently precedes or precipitates DPDR onset.⁶

Risk factors

• Childhood emotional abuse and emotional neglect are the most consistently replicated risk factors, with stronger associations than physical or sexual abuse.^7-8
• Acute stress, panic attacks, and cannabis or hallucinogen intoxication are common precipitants of the first episode.^6,9
• Interpersonal trauma in adolescence and young adulthood is a frequent trigger.⁷

DPDR sits at the intersection of dissociation, anxiety, and altered interoception. Current models emphasize a top-down inhibition of emotional and bodily experience, mediated by frontolimbic circuits, as a defense against overwhelming affect.¹⁰

Neurobiology

• Functional imaging shows hyperactivation of prefrontal regions, particularly the dorsolateral and ventrolateral prefrontal cortex, with reciprocal hypoactivation of the Insula and limbic structures during emotional stimuli.^10-11
• Reduced autonomic reactivity to emotional stimuli has been demonstrated, consistent with the subjective report of emotional numbing.¹¹
• Glutamatergic and endogenous opioid systems are implicated; ketamine and other NMDA antagonists can induce acute depersonalization in healthy volunteers.¹²
• Cannabinoid receptor activation, particularly via high-THC cannabis, can trigger persistent symptoms in vulnerable individuals.⁶

Genetics and developmental factors

• Heritability estimates for dissociative traits range from 50-60% in twin studies, though no specific susceptibility genes have been confirmed.¹³
• Insecure attachment and disrupted early caregiving relationships are associated with later dissociative symptomatology.^7-8

Integrative model

• Contemporary models frame DPDR as a hard-wired defensive response in which corticolimbic inhibition dampens overwhelming affect, producing the characteristic detachment and emotional muting.¹⁰
• Persistence is maintained by anxious self-monitoring, catastrophic appraisals ("I am losing my mind"), and avoidance, which is the target of cognitive-behavioral interventions.¹⁴

DSM-5-TR places depersonalization/derealization disorder among the dissociative disorders. The defining feature is persistent or recurrent detachment from self or surroundings with preserved reality testing — patients know the experiences are not literally true.¹⁵

DSM-5-TR criteria (summary)

• Persistent or recurrent experiences of Depersonalization, Derealization, or both.¹⁵
  • Depersonalization: feelings of unreality, detachment, or being an outside observer of one's thoughts, feelings, body, or actions, often with emotional numbing, distorted sense of time, or a sense that the self is unreal.¹⁵
  • Derealization: experiences of unreality or detachment from surroundings, with people or objects experienced as dreamlike, foggy, lifeless, or visually distorted.¹⁵
• Reality testing remains intact during the experiences, distinguishing DPDR from psychotic disorders.¹⁵
• Symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.¹⁵
• The disturbance is not attributable to a substance, another medical condition, or another mental disorder such as schizophrenia, panic disorder, MDD, acute stress disorder, PTSD, or another dissociative disorder.¹⁵

Specifiers and course modifiers

• DSM-5-TR does not specify formal severity levels or course modifiers, but clinicians typically document acute (less than 6 months) versus persistent (more than 6 months) course and predominant symptom type (depersonalization, derealization, or mixed).¹⁵

ICD-11 differences

• ICD-11 classifies depersonalization-derealization disorder (6B66) within the dissociative disorders chapter, with criteria closely paralleling DSM-5-TR.¹⁶
• ICD-11 explicitly emphasizes the ego-dystonic nature of the experiences and requires that symptoms not occur exclusively during another mental, behavioral, or neurodevelopmental disorder.¹⁶

Patients describe a striking, hard-to-articulate experience of unreality. The language is often metaphorical — "behind glass," "in a fog," "watching a movie of my life" — and the consistency of these descriptions across cultures is itself a diagnostic clue.^4,17

Core symptom clusters

• Anomalous body experience: feelings of being disembodied, having a body that is not one's own, or watching oneself from outside.^4,17
• Emotional numbing: muted or absent emotional responses to events that should evoke feeling, often distressing in itself.^4,17
• Anomalous subjective recall: memories feel as though they happened to someone else, with intact factual recall.^4,17
• Derealization: surroundings feel two-dimensional, dreamlike, or visually altered, with intact visual acuity.^4,17
• Altered time experience: subjective time slowing, speeding, or feeling discontinuous.^4,17

Course and prognosis

• Onset is typically acute, often triggered by an identifiable event such as a panic attack, cannabis intoxication, or interpersonal stressor.^4,9
• Roughly two-thirds of patients describe a chronic, continuous course; one-third describe episodic symptoms with discrete remissions.⁴
• Average duration before correct diagnosis is 7-12 years, reflecting persistent underrecognition.^4,18

Red flags suggesting an alternative diagnosis

• Onset after age 40, especially with neurological signs, suggests temporal lobe pathology or another medical cause.^4,19
• Loss of reality testing or fixed delusional elaboration suggests a primary psychotic disorder.¹⁵
• Discrete amnestic episodes with identity confusion suggest dissociative identity disorder or dissociative amnesia.¹⁵

Depersonalization and derealization phenomena are symptoms before they are a disorder. Most patients with these experiences have another primary diagnosis — most commonly panic disorder, PTSD, or a depressive episode — and DPDR is diagnosed only when symptoms are persistent, distressing, and not better explained elsewhere.¹⁵

Primary psychiatric differentials

• Panic disorder: depersonalization and derealization are criterion B symptoms of panic attacks; DPDR is diagnosed only if symptoms persist between attacks and cause independent impairment.¹⁵
• PTSD and acute stress disorder: dissociative symptoms occur during or after trauma; the dissociative subtype of PTSD is diagnosed when depersonalization or derealization predominates alongside full PTSD criteria.^15,20
• Major depressive disorder: emotional numbing in severe MDD can mimic depersonalization; treating the depression often resolves the dissociative experience.¹⁵
• Generalized and social anxiety disorders: anxious self-monitoring can produce transient depersonalization without meeting DPDR criteria.¹⁵
• Schizophrenia and other psychotic disorders: differentiated by loss of reality testing, delusional elaboration, and positive symptoms.¹⁵
• Other dissociative disorders: dissociative identity disorder and dissociative amnesia involve identity disturbance or amnestic gaps not present in DPDR.¹⁵
• Borderline personality disorder: stress-induced dissociation is a diagnostic feature, distinguished by transient course and pervasive identity disturbance.¹⁵
• Obsessive-compulsive disorder: existential or "what is real" obsessions can resemble depersonalization but have an ego-dystonic, intrusive quality with compulsive checking.²¹

Medical and neurological mimics

• Temporal lobe epilepsy and complex partial seizures: ictal or interictal depersonalization, particularly with associated automatisms, déjà vu, or olfactory aura.¹⁹
• Migraine with aura: visual derealization phenomena, classically described as the Alice in Wonderland syndrome, particularly in children and adolescents.²²
• Vestibular disorders: persistent postural-perceptual dizziness (PPPD) overlaps phenomenologically with derealization.²³
• Hypoglycemia, hypoxia, severe anemia, and electrolyte disturbance.⁴
• Thyroid disease, particularly hyperthyroidism with panic-like features.⁴
• Autoimmune and limbic encephalitis, including anti-NMDA receptor encephalitis, particularly in young women with rapid neuropsychiatric change.²⁴
• Traumatic brain injury and post-concussive syndromes.⁴

Substance-induced presentations

• Cannabis, especially high-potency THC products, is the most common precipitant in adolescents and young adults.^6,9
• Hallucinogens (LSD, psilocybin) and dissociatives (ketamine, PCP, dextromethorphan) can produce acute and, in some cases, hallucinogen persisting perception disorder.^12,25
• Alcohol withdrawal, stimulant intoxication, and synthetic cannabinoid use should be considered.⁶
• Prescription medications inducing depersonalization are described mainly in case reports rather than systematic data and should be considered when symptom onset closely follows a new drug.²⁹

Assessment begins with naming the experience for the patient — many present convinced they are "going crazy" and are relieved to learn the syndrome has a name. A structured interview, focused medical workup, and validated rating scale anchor the diagnosis.^4,18

Clinical interview essentials

• Detailed phenomenological description of the experiences in the patient's own words, with attention to onset, triggers, and temporal course.^4,18
• Substance use history including cannabis potency, frequency, and timing relative to symptom onset.^6,9
• Trauma history, with particular attention to childhood emotional abuse and neglect.^7-8
• Screening for panic, depression, PTSD, OCD, and suicidality, given high comorbidity.^2,5
• Family psychiatric history.⁴

Validated rating scales

• Cambridge Depersonalisation Scale (CDS): 29-item self-report, the most widely used and best-validated measure; scores above 70 are highly suggestive of DPDR.²⁶
• Dissociative Experiences Scale (DES) and DES-Taxon: broader dissociation screen with depersonalization/derealization subscale.²⁷
• Structured Clinical Interview for DSM Dissociative Disorders (SCID-D): gold-standard structured diagnostic interview.²⁸

Medical workup

• Targeted history and neurological examination first; broad untargeted labs add cost without yield.⁴
• TSH, CBC, comprehensive metabolic panel, and urine toxicology are reasonable baseline studies in new presentations.⁴
• EEG when episodic symptoms, automatisms, postictal confusion, or atypical features suggest temporal lobe epilepsy.¹⁹
• Brain MRI when neurological signs, late-onset presentation, or rapid progression raise concern for structural or autoimmune disease.^4,24
• Autoimmune encephalitis panel in young patients with rapid neuropsychiatric change and additional features such as movement disorder, seizures, or autonomic instability.²⁴

No medication or psychotherapy has FDA approval specifically for DPDR, and the evidence base is sparse compared with most psychiatric disorders. Treatment is therefore pragmatic: address comorbid conditions aggressively, treat the depersonalization symptoms with psychotherapy as the primary modality, and use pharmacotherapy as an adjunct.^14,29

Pharmacotherapy

• No medication is FDA-approved for DPDR, and randomized trial evidence is limited to small studies with heterogeneous outcomes.^29-30
• SSRIs and SNRIs are commonly used to treat comorbid depression and anxiety; symptom improvement is often attributable to comorbidity relief rather than direct antidissociative effect.^29-30
• Lamotrigine as monotherapy has shown mixed results; one small randomized controlled trial was negative, while open-label data suggested benefit as an adjunct to SSRIs.^31-32
• Naltrexone (50-100 mg/day) has shown modest benefit in small open-label studies, consistent with endogenous opioid involvement.³³
• Benzodiazepines may provide acute relief of associated anxiety but risk dependence and can worsen dissociation in some patients; long-term use is not recommended.²⁹
• Antipsychotics are not indicated unless required for a comorbid disorder; they do not target DPDR symptoms and carry significant adverse effects.²⁹

Psychotherapy

• Cognitive Behavioral Therapy (CBT) tailored for DPDR has the strongest evidence base, targeting catastrophic appraisals ("I am losing my mind"), symptom monitoring, and avoidance behaviors.^14,34
• A specialized 12-20 session protocol developed at the Maudsley showed clinically meaningful reductions in CDS scores in an open trial.¹⁴
• Trauma-focused psychotherapies (trauma-focused CBT, EMDR) are appropriate when DPDR is comorbid with or sequela of PTSD; evidence in primary DPDR is limited.^34-35
• Psychoeducation and grounding techniques — sensory anchoring, paced breathing, attentional refocusing — reduce symptom-driven distress even when symptoms persist.¹⁴
• Mindfulness-based approaches show preliminary promise but require careful introduction, as untrained interoceptive focus can intensify symptoms.³⁶

Neuromodulation

• Repetitive transcranial magnetic stimulation (rTMS) targeting the right temporoparietal junction or right ventrolateral prefrontal cortex has shown preliminary benefit in small open-label and pilot controlled trials.^37-38
• ECT is not indicated for DPDR alone and may worsen symptoms; it is reserved for severe comorbid depression with appropriate indications.²⁹

Adjunctive and lifestyle measures

• Cessation of cannabis, hallucinogens, and other dissociative substances is essential; continued use predicts poor response to any treatment.^6,9
• Sleep regulation, exercise, and limiting caffeine and alcohol reduce symptom intensity.¹⁴
• Treatment of comorbid panic disorder with CBT and SSRIs frequently produces parallel improvement in depersonalization symptoms.^14,29

The harms picture in DPDR is dominated by treatment-related adverse effects and by the consequences of underdiagnosis. The disorder itself is rarely lethal, but its impact on function, relationships, and healthcare utilization is substantial.^4,18

• SSRI and SNRI adverse effects include GI upset, sexual dysfunction, sleep disturbance, and discontinuation syndrome on abrupt cessation.^29-30
• Lamotrigine carries a low but recognized risk of serious cutaneous reactions including Stevens-Johnson syndrome, requiring slow titration.³¹
• Benzodiazepines risk tolerance, physiological dependence, cognitive impairment, and falls; some patients describe worsened dissociation.²⁹
• Antipsychotics, when inappropriately prescribed for unrecognized DPDR, contribute metabolic effects, sedation, and extrapyramidal symptoms without benefit.²⁹
• Underrecognition produces years of unnecessary medical workup, repeated emergency visits, and iatrogenic harm from cumulative imaging and inappropriate trials.^4,18
• The evidence base is small, dominated by open-label studies, short follow-up periods, and heterogeneous outcome measures; few high-quality RCTs exist.^29-30
• Most studies have been conducted in specialty referral samples, limiting generalizability to primary care and community presentations.^4,18

Age, developmental stage, and comorbidity shift the clinical picture and the differential. The two most clinically important groups are adolescents (the modal age of onset) and patients with comorbid PTSD.^4,20

Children and adolescents

• Mean age of onset is 16 years, making adolescent presentations the rule rather than the exception.^2,4
• Cannabis use, particularly initiation in early adolescence with high-potency products, is the most common precipitant in this age group.^6,9
• Differentiation from normative identity exploration and from emerging psychotic disorders requires longitudinal assessment.⁴

Perinatal considerations

• Systematic data on DPDR in pregnancy and the postpartum period are sparse, and the disorder is not specifically addressed in major perinatal psychiatry references.²⁹
• Postpartum dissociative symptoms more commonly reflect postpartum depression, anxiety, or PTSD related to traumatic delivery, and these conditions should be evaluated first.^20,29

Comorbid PTSD

• The dissociative subtype of PTSD, characterized by prominent depersonalization or derealization, is recognized in DSM-5-TR and predicts a more complex treatment course.^15,20
• Trauma-focused therapies should be paced carefully; abrupt exposure can intensify dissociation.³⁵

Geriatric considerations

• New-onset DPDR after age 40 is rare and should prompt thorough medical and neurological evaluation before psychiatric attribution.^4,19
• Cognitive impairment, delirium, and temporal lobe pathology become more likely differentials with advancing age.¹⁹

Cultural considerations

• The phenomenology of depersonalization and derealization is remarkably consistent across cultures, though idioms of distress vary.¹⁷
• Religious or spiritual framings of dissociative experience must be respected and differentiated from psychopathology.¹⁷

DPDR tends toward chronicity, but symptom reduction and functional recovery are achievable with appropriate treatment. Prognosis is shaped more by comorbidity and ongoing substance use than by the dissociative symptoms themselves.^4,18

• Approximately two-thirds of patients describe a chronic, continuous course; one-third have an episodic course with discrete remissions.⁴
• Spontaneous remission occurs in a minority, particularly when symptoms were precipitated by an acute event and the precipitant resolves.⁴
• Better prognostic factors include acute onset with identifiable precipitant, absence of comorbid personality disorder, and engagement in psychotherapy.^4,14
• Worse prognostic factors include continued cannabis or hallucinogen use, severe childhood trauma, and prominent comorbid borderline personality features.^6-7
• Suicide risk is elevated primarily through comorbid depression rather than DPDR symptoms themselves, but warrants routine screening.^2,5
• Functional outcomes vary widely; severe cases produce occupational disability comparable to severe depression.^4,18

DPDR rarely presents as a psychiatric emergency in its own right, but emergency presentations are common because the experience is terrifying and patients fear they are losing their minds or having a stroke.^4,18

• Reality testing is intact; patients presenting with loss of reality testing or delusional elaboration require evaluation for primary psychosis.¹⁵
• Acute panic attacks with prominent depersonalization respond to standard panic management; reassurance about the benign nature of the dissociative symptoms is itself anxiolytic.¹⁴
• Substance-induced dissociation (cannabis, hallucinogens, ketamine) typically resolves with substance clearance; persistence beyond expected pharmacokinetics warrants reevaluation.^6,25
• Suicide risk assessment should focus on comorbid depression, hopelessness about chronicity, and substance use rather than dissociative symptoms alone.^2,5
• Hospitalization is rarely required for DPDR alone and is reserved for safety concerns from comorbid conditions.⁴

DPDR sits in a contested space between dissociation, anxiety, and neurobiological models of altered self-experience. Several questions remain unsettled.^10,29

• Whether DPDR is best conceptualized as a primary dissociative disorder, an anxiety spectrum condition, or a disorder of interoception and self-modeling remains debated.^10-11
• The role of cannabis in causing versus unmasking DPDR is unresolved; population-level data implicate high-potency cannabis as a precipitant in vulnerable individuals, but causal pathways are unclear.^6,9
• Treatment evidence is dominated by small open-label studies; the absence of large RCTs leaves first-line pharmacotherapy effectively unestablished.^29-30
• The dissociative subtype of PTSD overlaps substantially with comorbid DPDR; whether these are distinct entities or descriptions of the same phenomenon at different boundaries is debated.²⁰
• Whether rTMS targeting temporoparietal or prefrontal regions will translate from small pilots to standard care depends on adequately powered controlled trials yet to be completed.^37-38
• Diagnostic underrecognition persists despite a stable prevalence and well-described phenomenology; the average 7-12 year diagnostic delay is a quality-of-care problem rather than a scientific one.^4,18

• DPDR has a lifetime prevalence of approximately 1-2%, comparable to schizophrenia, and is dramatically underrecognized.^1-2
• The mean age of onset is 16 years, and 95% of cases begin before age 25; new onset after 40 should prompt neurological workup.^2,4
• Reality testing remains intact in DPDR — patients know the experiences are not real, distinguishing it from psychotic disorders.¹⁵
• Depersonalization and derealization are criterion B symptoms of panic attacks; DPDR is diagnosed only when symptoms persist independently.¹⁵
• The dissociative subtype of PTSD is characterized by prominent depersonalization or derealization symptoms.^15,20
• Childhood emotional abuse and neglect are more strongly associated with DPDR than physical or sexual abuse.^7-8
• Cannabis, particularly high-potency THC, is the most common substance precipitant in adolescents and young adults.^6,9
• The Cambridge Depersonalisation Scale (CDS) is the most widely used and best-validated rating instrument.²⁶
• No medication has FDA approval for DPDR; SSRIs are used primarily to treat comorbid anxiety and depression.^29-30
• Lamotrigine monotherapy was negative in one small RCT but open-label adjunctive data are mixed.^31-32
• CBT tailored for DPDR, particularly the Maudsley protocol, has the strongest psychotherapy evidence base.¹⁴
• Temporal lobe epilepsy and anti-NMDA receptor encephalitis are critical medical mimics to exclude.^19,24
• Functional imaging shows prefrontal hyperactivation with limbic and insular hypoactivation during emotional stimuli.^10-11
• Approximately two-thirds of patients have a chronic continuous course; one-third have an episodic course.⁴
• Continued cannabis use predicts poor treatment response and should be addressed before or alongside any pharmacotherapy.^6,9

No external funding. No conflicts of interest declared. Peer-review status: pending.